Medicines A–Z
A
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Atropine tablets | For Myaesthenia Gravis only |
|
 |
Avacopan (Tavneos®) | ||
|
Avalglucosidase | ||
|
Avatrombopag | ||
|
Avatrombopag (Doptelet®) | ||
|
Aveeno cream | Amber - oncology use Green - paediatrics only |
|
|
Avelumab (Bavencio®) | ||
|
Aviptadil 25mcg / Phentolamine 2mg intracavernosal injection (Invicorp®) | Approved on formulary December 2017. Specialist initiation. Third line after oral PDE-5 inhibitors failed and patient not responding to or intolerant of alprostadil. To be reviewed within 12 months to assess alprostadil supply issues and patent expiry |
|
|
Axicabtagene ciloleucel (Yescarta®) |
|
|
|
Axitinib | National CDF list |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
